@article{JTD22947,
author = {David Crossman and Alexander M. K. Rothman},
title = {Interleukin-1 beta inhibition with canakinumab and reducing lung cancer—subset analysis of the canakinumab anti-inflammatory thrombosis outcome study trial (CANTOS)},
journal = {Journal of Thoracic Disease},
volume = {10},
number = {Suppl 26},
year = {2018},
keywords = {},
abstract = {In the field of cardiovascular disease, the reporting of the Cantos trial was eagerly wait in 2017. It did not disappoint, and we have previously reviewed the cardiovascular implications of IL-1 beta inhibition in patients with cardiovascular risk, defined as a prior myocardial infarction and a hs-CRP >2 mg/L, in this journal (1).},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/22947}
}